RxDoctor Payments Data

Claudia Hernandez, MD

Family Medicine · Pico Rivera, CANPI 1518006550

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 33 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$613
  • Lilly USA, LLC$260
  • Amgen$207
  • Bayer$32
  • ERMI LLC$19
  • Merck$18
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,15799%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$613
Lilly USA, LLC13$260
Amgen3$207
Bayer2$32
ERMI LLC1$19
Merck1$18
AstraZeneca1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$24,783
Medicare patients
72
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$74,642
OzempicSemaglutide66$71,625
RybelsusSemaglutide31$69,056
JardianceEmpagliflozin44$62,876
EliquisApixaban40$58,905
JanuviaSitagliptin Phosphate26$39,989
JanumetSitagliptin Phos/Metformin Hcl31$34,219
TradjentaLinagliptin28$25,961
FarxigaDapagliflozin Propanediol17$23,504
Tresiba Flextouch U-200Insulin Degludec17$10,033
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$9,691
VascepaIcosapent Ethyl18$8,014
Atorvastatin Calcium597$6,151
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,954
Icosapent Ethyl14$3,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$613$140,68197 claims
Lilly USA, LLCMounjaro$260$74,64256 claims
MerckJanuvia, Janumet$18$74,20857 claims
AstraZenecaFarxiga$17$23,50417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Pico Rivera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →